GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » PROCEPT BioRobotics Corp (NAS:PRCT) » Definitions » Debt-to-EBITDA

PROCEPT BioRobotics (PROCEPT BioRobotics) Debt-to-EBITDA : -0.86 (As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is PROCEPT BioRobotics Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

PROCEPT BioRobotics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $1.7 Mil. PROCEPT BioRobotics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $79.7 Mil. PROCEPT BioRobotics's annualized EBITDA for the quarter that ended in Mar. 2024 was $-94.9 Mil. PROCEPT BioRobotics's annualized Debt-to-EBITDA for the quarter that ended in Mar. 2024 was -0.86.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for PROCEPT BioRobotics's Debt-to-EBITDA or its related term are showing as below:

PRCT' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -1.22   Med: -0.98   Max: -0.58
Current: -0.86

During the past 5 years, the highest Debt-to-EBITDA Ratio of PROCEPT BioRobotics was -0.58. The lowest was -1.22. And the median was -0.98.

PRCT's Debt-to-EBITDA is ranked worse than
100% of 431 companies
in the Medical Devices & Instruments industry
Industry Median: 1.21 vs PRCT: -0.86

PROCEPT BioRobotics Debt-to-EBITDA Historical Data

The historical data trend for PROCEPT BioRobotics's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PROCEPT BioRobotics Debt-to-EBITDA Chart

PROCEPT BioRobotics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-EBITDA
-0.58 -1.22 -1.07 -0.98 -0.81

PROCEPT BioRobotics Quarterly Data
Dec19 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.75 -0.85 -0.88 -0.79 -0.86

Competitive Comparison of PROCEPT BioRobotics's Debt-to-EBITDA

For the Medical Devices subindustry, PROCEPT BioRobotics's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


PROCEPT BioRobotics's Debt-to-EBITDA Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, PROCEPT BioRobotics's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where PROCEPT BioRobotics's Debt-to-EBITDA falls into.



PROCEPT BioRobotics Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

PROCEPT BioRobotics's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(1.683 + 77.521) / -98.095
=-0.81

PROCEPT BioRobotics's annualized Debt-to-EBITDA for the quarter that ended in Mar. 2024 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(1.701 + 79.686) / -94.912
=-0.86

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Mar. 2024) EBITDA data.


PROCEPT BioRobotics  (NAS:PRCT) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


PROCEPT BioRobotics Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of PROCEPT BioRobotics's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


PROCEPT BioRobotics (PROCEPT BioRobotics) Business Description

Traded in Other Exchanges
N/A
Address
900 Island Drive, Redwood, CA, USA, 94065
PROCEPT BioRobotics Corp is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. It develops, manufactures, and sells the AquaBeam Robotic System, an advanced, image-guided, surgical robotic system for use in minimally invasive urologic surgery, with an initial focus on treating benign prostatic hyperplasia, or BPH. The company's assets are based in the United States. Its revenue is generated from sales of the AquaBeam Robotic System and the accompanying single-use disposable handpieces.
Executives
Alaleh Nouri officer: SVP, GEN COUNSEL, CORP. SEC. 1310 CHESAPEAKE TERRACE, SUNNYVALE CA 94089
Kevin Waters officer: Senior VP, CFO 1310 CHESAPEAKE TERRACE, SUNNYVALE CA 94089
Frederic H Moll director C/O INTUITIVE SURGICAL INC, 950 KIFER ROAD, SUNNYVALE CA 94086
Wood Morgan Colby director C/O PROCEPT BIOROBOTICS CORPORATION, 900 ISLAND DRIVE, REDWOOD CA 94065
Reza Zadno director, officer: President, CEO 2710 SAND HILL ROAD, SUITE 200, MENLO PARK CA 94025
Hisham Shiblaq officer: SVP, Commercial Operations C/O PROCEPT BIOROBOTICS CORPORATION, 900 ISLAND DRIVE, REDWOOD CITY CA 94065
Thomas M Krummel director C/O CALIFORNIA WATER SERVICE GROUP, 1720 N. FIRST STREET, SAN JOSE CA 95118
Viking Global Investors Lp 10 percent owner 600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901
Viking Global Opportunities Parent Gp Llc 10 percent owner 600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901
Dragsa 88 Llc 10 percent owner 55 RAILROAD AVE, GREENWICH CT 06830
Rose Sharon Shabet 10 percent owner 600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901
Viking Global Opportunities Illiquid Investments Sub-master Lp 10 percent owner 600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901
Viking Global Opportunities Gp Llc 10 percent owner 55 RAILROAD AVENUE, GREENWICH CT 06830
Viking Global Opportunities Portfolio Gp Llc 10 percent owner 600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901
David C. Ott 10 percent owner 600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901